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Abstract
Recently much progress was achieved in understanding the genetic etiology of lung
cancer. This progress, combined with the well understood role of environmental
causative risk factors, is leading to the development of new diagnostic and therapeutic
strategies to combat and prevent the lung cancer epidemic. Environmental agents such as
tobacco smoke, radon, radiation, air and industrial pollutants are now well known to act
by damaging cancer-causing genes, thereby initiating transformation and clonal
development of transformed cells in the lung epithelium. We review the basic facts and
concepts in lung cancer pathogenesis describing involved cancer-causing genes, clonal
origin and development of initiated, pre-malignant cells into preinvasive and invasive
tumors and novel strategies for early diagnosis and treatment of lung tumors.
2Introduction
Despite the enormous progress achieved in molecular, genetic and clinical oncology in
the past several decades the problem of lung cancer continues to plague medicine. Since
the 1950s the incidence of lung cancer worldwide has been increasing and has reached
now the proportion of an epidemic that has not yet leveled-off (1-3). Lung cancer kills
yearly more than 170, 000 patients in the USA alone (2) and over a million around the
world (3). In the United States, these deaths are more than those attributable to colon,
prostate and breast cancer combined. The sheer scale of this epidemic has heightened
efforts to understand the biology and molecular pathogenesis of lung cancer including
lung cancer-causing genes and their interaction with environmental factors involved in
cancer causation such as tobacco smoke, air pollutants and asbestos.
In this chapter we examine the basic facts and concepts in lung cancer pathogenesis.
We will cover the following topics: (1) genetic and gene models in lung cancer;
(2) cell models in lung cancer development including (a) lung embryology and
stem/precursor cells related to lung tumors, (b) molecular evolution of initiated cells and
field cancerization in the affected lung, (c) cellular evolution of the metaplasia-dysplasia-
carcinoma in situ-invasive cancer sequence of events in the affected lung, and (d)
molecular events in the obligatory sequence of progression to full blown invasive cancer
in the lung; (3) classification, diagnosis, and clinical course of lung cancers; (4) treatment
of all forms of lung cancers including (a) traditional combined regimens; (b) novel
molecular targets for drugs discovery; (c) immunotherapy protocols; (d)  gene therapy
and gene delivery to the lung; (5) environmental factors as causative agents in lung
3cancer pathogenesis and prevention of lung cancer; (6) optimism and pessimism for the
immediate future in the post-genome era  from the viewpoint of researchers, physicians,
and patients.
1. Genetic and gene models in lung cancer causation
Epidemiological studies of human cancer(s) have long established (since 1940-1950) that
carcinogenesis could be best approximated as a multistep process caused by genetic
changes that accumulate over time (4, 5). As many as 6 to 7 such changes were
considered necessary to bring about a full-blown malignancy that resulted in the patient’s
death. Later (in the 1960s), cell hybridization studies have established the recessive
nature of the malignant phenotype (6). These earliest findings followed by
monochromosome transfer experiments (7) held the promise of restoring the normal
phenotype to cancer cells and sow the seeds of the “brave new world” of cancer gene
therapy of today (8). Statistical analysis of familial and sporadic childhood
retinoblastoma (RB) and Wilms’ tumor (WT) have led Knudson to formulate the now
classical two-hit hypothesis which postulates that two mutations are required and rate-
limiting in the process of tumorigenesis (9, 10). In molecular terms, these double hits
have been attributed to the inactivation of both alleles of a gene(s) serving a tumor
suppressor function (hence, tumor suppressor gene(s), TSG) (9-11). Initially, there was
not much progress probably due to the technological limitations at the time. Later the
theory became amenable to a great range of applications and prompted an explosion of
results. Combined research efforts correlated genetic predisposition to cancer with
4specific abnormalities leading to the identification of a large number of oncogenes and
TSG(s) (12). With the genes in hand, the predictions of the theory were verified and the
mutated cancer-causing genes, oncogenes and TSGs, became the paradigm of genetic
etiology and pathogenesis of human inherited and common cancers. The changing
terminology in the field reflects the shift in the paradigm: from genes associated with
cancer to, finally, genes causing cancer. To summarize, inherited (12), initiating (13),
“gate keepers” (14), cancer-causing (our term) genes follow the two-hit proposition for
cancer causation. These genes (TSGs or oncogenes) are usually discovered in the
inherited family cancer syndromes through genetic mapping and positional cloning or
alternatively through somatic deletion mapping in tumors and/or established cancer cell
lines. Consistent with the two-hit proposition, the corresponding tumors show loss or
inactivating mutations in the wild type allele (in family syndromes) (12, 15) or both
alleles in sporadic tumors (in case of TSG) (15). In case of inherited activated oncogenes
(16) the tumors may show loss of the wild type allele with simultaneous
duplication/amplification of the mutant chromosome, or a second activating hit in the
wild type allele (17, 18); same events happen in corresponding sporadic tumors (15). The
net result of these rate-limiting genetic changes is a homozygous status for these cancer-
causing genes in tumors. The recently discovered haploinsufficient TSGs (19, 20)
apparently violate this rule. They predispose to cancer in the hemizygous state but do not
require a second genetic hit in the tumor. Apparently, the second hit in this model may
target another cancer haploinsufficient gene. Both cancer gene models apply to sporadic
malignancies arising from the same stem cell(s) (see below, pp. xx).
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correlate with the stepwise most likely ordered inactivation/loss of several (TSGs) and/or
with simultaneous activation of oncogenes (altogether not exceeding 6-7 events). While
the activation/inactivation of the first cancer-causing gene in a normal stem cell would
initiate malignant transformation, the subsequent changes in these initiated/transformed
cells would drive clonal expansion, development, and progression into a full-blown
tumor. The products of cancer-causing genes (oncogenes and TSGs) are components of
signal transduction pathways and signal integration mechanisms that control cellular
proliferation, differentiation, cell migration and/or apoptotic death. Identification of the
components of these signaling pathways will help to understand cancer pathogenesis and
lead to development of mechanism-based therapies (see below, pp. xx). It is important to
stress that TSG transfer studies have established that a single normal individual gene can
reverse the malignant phenotype despite the presence of other genetic defects (21, 22),
pointing at molecular marks that would later be targeted with new selective drugs and
other treatment modalities (23).
We now enumerate and describe briefly some of the most important cancer genes
(oncogenes, TSGs, growth related genes, death related genes) involved in the origin
and/or development of lung cancer(s) and then provide a tentative gene model of lung
cancer pathogenesis. Over a 100 oncogenes and about 50 TSGs have now been described
(15, 24) approaching the expected number of cancer genes (i.e. 200) as suggested by the
number of distinct human tumors (25). A comprehensive search of the human genome
draft sequence for paralogous sequences of known cancer genes did not result in finding
such genes (26, 27).
6Oncogenes
The RAS genes play a fundamental role in signal transduction pathways involved in
cellular proliferation and apoptosis interacting with other regulatory circuits of cell
growth and death (23, 28). Activation of the K-ras proto-oncogene by point mutations in
codon 12 accounts for over 90% of RAS mutations in lung cancer. It occurs in 50% of
lung adenocarcinomas and in 20% of all NSCLCs but not at all in SCLCs or other lung
tumors with neuroendocrine features  or squamous cell carcinomas. The K-ras codon 12
point mutations are found by PCR in bronchoalveolar cell lavage and predict poor
prognosis of these patients. The recently discovered RASSF1 TSG family (see below,
pp.xx) from the 3p21.3 lung and breast cancer region (22, 29-31) encodes proteins with a
RAS binding domain. We propose that the RASSF1 products sequester RAS proteins and
therefore negatively regulate their concentration in the cell. In this model, over-
expression of RAS or inactivation/loss of RASSF1would liberate RAS and drive
proliferation; similarly, the same endpoint would be obtained if mutated RAS protein
would not bind to RASSF1 protein. Consistently, the RASSF1 locus is silenced in about
100% of SCLCs and only in about 30-50% of NSCLCs (30, 31) correlating with the
frequency and distribution of RAS mutations.
The MYC genes comprise a family of related genes (c-myc, N-myc, L-myc) that encode
transcription factors of the BHLHB2 type. The product of c-myc forms a heterodimer
with Max and activates genes involved in growth control and apoptosis (32). The most
common abnormality involving the Myc genes in lung cancer is gene amplification or
7gene over-expression: over-expression with amplification reached 80-90% in SCLCs (23
but only 50% in NSCLC specimen without gene amplification (23).
The BCL-2 gene product is a key member of the normal pathway of programmed cell
death and when over-expressed protects cell from apoptosis (23). It is highly expressed in
SCLCs (33) and much less frequently in NSCLCs (34).
The ERB-2 gene encodes a receptor tyrosine kinase and due to amplification is over-
expressed in 25% of NSCLCs (23, 28) and rarely expressed in SCLCs (23, 28). It is a
biomarker of poor prognosis in NSCLCs (23) and a target for therapy with specific
antybodies (23). The related epidermal growth factor receptor, ERB-1, is activated in
lung cancer cells by over-expression (23).
The MDM-2 gene encodes an oncoprotein that binds to p53 and inhibits its
transcriptional activity (35). It also targets wild type p53 for ubiquitin-mediated
degradation (35, 36). It is rarely amplified in NSCLCs (37), however its product is
observed more frequently by immunohistochemistry and correlates with better prognosis
among patients without p53 accumulation (38).
The MST1R/RON gene ncodes a receptor tyrosine kinase (RTK) and together with Met
(see below) comprise a unique two-member RTK family involved in lung cancer. RON is
highly expressed in normal lung (39, 40), in SCLCs a truncated form of the mRNA is
universally expressed while in NSCLCs only the long apparently normal mRNA is
present (40). In lung cancer activating mutations in the tyrosine kinase domain were
extensively searched for but none were found yet (40). Recen ly, we discovered that the
RON/MST1R locus encodes also for a truncated protein that has a constitutively
activated tyrosine kinase domain and is encoded by the short mRNA in SCLCs (Angeloni
8et al, unpublished); similarly other investigators discovered a short form of Met (41) (see
below). These two RTKs form a unique two-member family and have an identical
modular and domain structure and therefore perform identical functions. We propose the
following model involving this family in developmental and adult growth and their
deregulation in tumor growth. In normal growth, the long form, RTK, and the short form,
TK, are never expressed simultaneously in the same cell; when the promoter of the long,
RTK form is silenced by de novo methylation (Angeloni et al, unpublished) the short
form, TK, is expressed by default. In this model, the TK form drives proliferation to
expand a specific cell population to a certain controlled number; then the RTK promoter
becomes activated again (by demethylation) and the RTK activated by specific ligand
binding drives differentiation of the expanded cell compartment. The net result is normal
growth. When coupled with programmed cell death this process would account for
homeostasis of adult tissues and organs. In SCLCs the RON RTK form is silenced and
the TK form highly expressed and becomes constitutively activated and oncogenic; the
mechanism of RTK activation in NSCLCs remains at present unknown.
The Met gene encodes a similar RTK and is involved in a number of human cancers (42)
including hereditary and sporadic papillary renal carcinomas as a cancer-causing gene
(17,18). The gene is expressed in normal lung (43) together with its ligand, HGF (43).
This pair is also expressed in NSCLCs and high levels of HGF were associated with poor
prognosis (44).
Death related genes
9The FAS gene product and its ligand, FASL activate cell death pathway(s) in many cell
systems (23). In the immune T-cells binding of FASL to the cognate receptor FAS,
activates apoptosis and serves as a negative regulator of the immune response to tumor
cells. Tumors employ a variety of strategies to avoid surveillance and destruction by the
immune system (23). The FASL product is expressed universally, in all SCLC/NSCLC
cell lines and in 80% of SCLC and 93% of NSCLC tumors mediating death of the
immune T-cells (23). Since as a rule the tumor cells do not express the FAS receptor they
avoid autocrine-induced FAS-mediated death (23). Recently, the candidate TSG locus on
3p21.3, LUCA-15 (29), was shown to suppress FAS-mediated apoptosis in Jurkat cells
(45) by up-regulating the expression of the apoptosis inhibitor, BCL-2 (23), further
implying a role in tumor growth.
Growth factors
Several growth factors (such as gastrin-releasing peptide, substance P, bombesin, EGF,
TGF alpha and beta and others) and their cognate receptors show dysregulated expression
in lung cancer creating a network of autocrine and paracrine pathways (23,46) that results
in uncontrolled proliferation. Recently these pathways were targeted for treatment by
antibodies (23), and antisense technologies (23,46). Recently the insulin-like growth
factors, IGF-1 and IGF-2 and their receptors were shown to be important in the
development of all forms of lung cancer (23) prompting clinical trials with somatostatin
to block the IGF-IGF-receptor complex function (23).
Tumor suppressor genes in lung cancer
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The paramount importance of tumor suppressor gene (TSG) inactivation in human cancer
causation was stressed and briefly discussed above along with cancer gene models (see
pp. xx). Much progress was achieved earlier in the identification of TSGs involved in
lung cancer development and /or progression but only recently novel TSGs residing in
the chromosome 3p21.3 region were identified that represent bona fide lung cancer-
causing genes (22, 29-31, 47).
Two critical cell cycle regulatory pathways, namely the RB (23, 48) and p53 (23, 35)
TSG pathways are deregulated in all types of lung cancer consistent with the general
view of cancer as a “disease of the cell cycle” (23, 35, 48).
The RB pathway controls the G1 checkpoint and allows the transition into the G2/S-
phase of the cell cycle (23, 48). Incoming growth-promoting signals transduced from
cell-surface receptors to the nuclei cause rapid and transient elevation in D-cyclins in
early G1-phase. In particular, cyclin D1 activates Cdk4/6 kinase that phosphorylates the
RB protein (pRB) resulting in the release of the transcription factor E2F which in turn
activates S-phase genes including thymidine kinase, Cdc6, c-Myc, and DNA polymerase-
alpha (48). The RB pathway also includes the p16/MTS1 (multiple tumor suppressor
gene from 9p21) which serves a Cdk inhibitor function for the D-Cdk4/6 dimers, causing
G1 arrest. Deregulated passage trough the G1 checkpoint into S-phase would result either
from inactivation/loss of one of the tumor suppressors (p16 or pRB) or activation of
cyclin D1 by mutations or over-expression (48). Loss of RB or p16 or cyclin D1 over-
expression occurs in most, if not all, human cancers including lung cancers, and
constitutes a necessary step in cancer development and /or progression (48). In addition,
the E2F gene is frequently over-expressed in lung cancer (23). Clearly, RB is a cancer-
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causing gene for retinoblastoma and osteosarcoma (49) while p16 causes familial
melanoma (50).
The p53 pathway.  The p53 TSG is the most frequently mutated gene in cancer (35) and
is mutated in 50-60% of NSCLCs (23, 35) and 70-90% of SCLCs (23, 35). Mutations in
p53 commonly reflect exposures to environmental carcinogenes, e.g. cigarette smoke in
lung cancer. The p53 protein has been frequently referred to as the “guardian of the
genome” (35) because the p53 gene is induced by DNA damage that leads to cell cycle
arrest at the G1/S border until DNA is repaired. If repair is delayed, it steers the damaged
cells into apoptosis (35). Cell cycle arrest is achieved by p53 inducing the expression of
p21, a Cdk inhibitor. Alternatively, apoptosis is induced by bax whose expression is
again induced by p53 (35). Loss of p53 therefore results in deregulated cell cycle
progression and accumulation of DNA damage i.e. mutations or genomic instability.
The Li-Fraumeni cancer family syndrome is caused by germ line mutations in the p53
TSG (49) and manifest multiple types of cancer that do not include lung cancer (50);
however surviving affected patients may develop multiple primary lung cancers of
different types (51). They usually occur late and are associated with heavy smoking
suggesting that p53 is not a cancer-causing gene in lung cancer.
The RASSF1 genes from 3p21.3.  Loss of genetic material from chromosome 3p21.3 by
heterozygous or homozygous deletions is the earliest, most likely the first, genetic event
observed in many types of lung pre-malignant lesions. It was also observed in
histologically normal-looking, tobacco smoke-exposed, matching bronchial epithelium
(52), indicating the presence of activated lung cancer-causing genes. Recently, 3p21.3
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was extensively analyzed and all resident genes were cloned and characterized (29). At
present, the resident RASSF1 genes, RASSF1/A and RASSF1/C, driven from separate
CpG-type promoters and sharing four terminal exons, were shown to represent bona fide
TSGs (22, 29-31, 47). The corresponding proteins share a common RAS binding domain;
in addition, RASSF1/A contains a diacylglycerol (DAG) and SH2 domains in the amino-
terminal half of the protein. The presence of these domains suggest the RASSF1 protein
could play fundamental role(s) in signal transduction pathways from the cell surface to
the nucleus. We hypothesize that the RASSF1 protein binds RAS and thereof controls the
amount of RAS available for signal transduction. Therefore, inactivation or loss of
RASSF1 would result in “over-expression” of RAS, which would in turn, drive malignant
proliferation. RASSF1/A is silenced by promoter hypermethylation in over 90% of
SCLCs and SCCs and in about 50% NSCLCs (correlating with the mutational status of
RAS) and is able to suppress growth of lung cancer cells in culture and tumor formation
in mice (22, 29-31). Moreover, the gene is silenced in many human cancers including
kidney (22), breast (31), head and neck (53) and prostate (Kuzmin et al, unpublished,
2001), probably due to its ability to control RAS. It is therefore tempting to assume that
RASSF1/A is a multiple tumor suppressor gene and is probably involved in development
or progression of a majority of human tumors. However in lung cancer it is rather a
gatekeeper cancer-causing TSG because its inactivation/silencing is probably the first
abnormality in the sequence of events leading to pre-malignant lesions and then invasive
cancer (see below, pp. xx). The RASSF1/C gene is involved in the development and/or
progression of ovarian cancer (54).
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The HYAL2/LUCA2 gene from 3p21.3 region.  Recently, this candidate TSG that
resides in the 120 kb critical 3p21.3 segment (29) has been identified as a cell-surface
GPI-anchored receptor for jaagsiekte sheep retrovirus (JSRV) cell entry  (47). JSRV is an
ovine retrovirus. In sheep, it causes a contagious form of lung cancer that arises from
epithelial cells in the lower airway including type II alveolar and bronchiolar epithelial
cells (55). The sheep tumors exhibit histological features similar to many human
pulmonary adenocarcinomas, including bronchiolo-alveolar carcinoma (BAC), whose
incidence is rising and has now replaced the incidence of SCC (56). It was also shown
that the Env gene of JSRV could induce foci formation in rodent cultured fibroblasts (47)
and human immortalized bronchial epithelial cells (Danilkovitch et al, unpublished,
2001), thus identifying Env as the oncogenic factor in lung cancer pathogenesis. The
pathogenesis of BAC is quite peculiar and could be explained by infection with a human
retrovirus similar to JSRV, therefore suggesting the possibility of viral etiology of BAC.
It appears that JSRV does not cause lung cancer in humans having occupational exposure
to this virus (55). However, a recent study showed that antiserum directed against the
JSRV capside protein cross-reacted with 30% of human pulmonary adenocarcinoma
samples but not with normal lung tissue, or many adenocarcinoma samples from other
tissues (57), supporting the proposition that related viruses may indeed be involved in
human lung cancer. The Env of this hypothetical virus could sequester the product of the
HYAL2/LUCA2 TSG and thus liberate an oncogenic factor negatively controlled by
HYAL2/LUCA2 TSG. This factor, together with the Env protein, would drive malignant
transformation of bronchial-alveolar epithelial cells. Experiments with JSRV transformed
human bronchial epithelial cells (Danilkovitch et al, unpublished, 2001) provide support
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for this model. The viral etiology for BAC has a precedent in viral etiology of several
human cancers that include cervical cancer and HPV (58) and mesothelioma and SV40
(59). Importantly, both SV40 and HPV proteins sequester TSG products, p53 and pRB
respectively (35, 48) inactivating the respective pathways.
Lung cancer gene models
Large and punctuated allelic losses in the chromosome 3p21.3 region are present in
perhaps all types of lung cancer (29, 52), their pre-malignant precursor lesions (52) and
even in the histologically normal bronchial epithelium of current and former smokers (29,
52). This indicates that TSG(s) residing in such chromosomal region are likely to play a
causative role in the earliest steps of lung cancer pathogenesis. Chromosome-transfer
studies demonstrating the presence of a tumor-phenotype suppressing function in 3p21.3,
lends further support to this proposition (60). Increasing evidence suggests that more than
one gene in the 3p21.3 region (which contains at least 8 critical candidate TSGs  - see
above, pp.xx and ref. 29) can serve as TSG in lung cancer causation. Among these genes
some conform to the classical two-hit model requiring inactivation/or loss/or silencing of
both alleles of the gene (homozygous, -/-, phenotype), while others may function as
haploinsufficient TSGs one allele of which is still expressed in the tumor (hemyzygous, -
/+ phenotype). Since the acquisition of other genetic modifications is still rate-limiting in
causing cancer (15), another mutation in a different gene would appear to be required in
the haploinsufficient cancer model.  It is tempting to assume that it could be a mutation in
a second known TSG such as p16, p53, and RB, all of which are frequently mutated in
many common cancers bearing 3p21.3 allele loss, including lung cancers (29).
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Consistently, allele loss at these genetic loci (at 9p21, 13q14 and 17p13) occurs after 3p
allele loss at a later stage of carcinogenesis when histologically dysplastic or carcinoma
in situ lesions become evident (see below, pp .xx).
Lung embryology (see below, pp.xx) identifies lung stem cells as the primitive columnar
epithelial cells derived from the primordial upper gut at days 40-45 of development (61).
These columnar cells first differentiate into neuroendocrine cells (probably, the cells of
origin of SCLCs), and a variety of multipotent bronchial epithelia cells (probable the cells
of origin of NSCLCs).  In fact some lung cancers, exhibit within the same tumor
histologic features of several lung cancer types indicating a possible common stem cell of
origin (29).  The embryology of the lung would therefore suggest that the same genes
could be involved in both SCLC and NSCLC carcinogenesis.
The following model of lung cancer pathogenesis based on these developing concepts
and accumulated evidence is proposed.  Consequent to smoking (or other environmental
pollutants) damage, 3p21.3 allele loss occurs in thousands of different sites throughout
the respiratory epithelium leaving the putative 3p21.3 TSGs haploinsufficient.  These
initiated (3p21.3 hemizygous) cells proliferate and spread throughout the lung epithelium
and/or form clonal patches estimated to consist of ~50-100,000 cells (~15-17 doublings).
The next hit could occur either in the second allele of a classical TSG (e.g. RASSF1) or,
as required in the haploinsufficient model, in another cancer-causing gene (such as RB,
p53, p16 or “gene X”), leading to the next stages of invasive cancer.  The RB and p53
genes are mutated in nearly 100% of SCLC samples, while mutations of p53 occur in
50% of NSCLC and some form of p16 inactivation (also inactivating the RB pathway)
occurs in a very large fraction of NSCLCs (23). In the classical homozygous model the
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3p21.3 TSG first undergoes allele loss and then a second inactivating event (either as
uncommon mutation or loss of expression through promoter hypermethylation) which is
required to allow the clonal outgrowth of these initiated cells.  At any rate, the nearly
universal loss of 3p21.3 DNA in SCLC and squamous cell carcinoma of the lung (SCC),
and its occurrence in over 50% of adenocarcinomas of the lung, suggest that these
deletions are obligatory, rate-limiting steps in the pathogenesis of many lung cancers, if
not all. It should also be noted that allele loss that includes 3p21.3 and the immediately
surrounding 3p21 regions would lead to a condition of hemyzygosity for many other
predisposing genes residing in the area. These include MLH1, TGFRII, beta-catenin,
RON, and Wnt5, which also could contribute to malignant transformation.  Functional
testing by gene transfer into lung cancer cells (29-31) and gene disruption strategies in
mice are necessary to test the theoretical model and discover all putative TSGs in 3p21.3,
and also to produce mouse models of lung cancer. Such experiments are now in progress.
Studies of familial lung cancer risk, including data from lung cancer occurring in young
non-smoking individuals, are compatible with Mendelian codominant inheritance of a
rare major autosomal gene that produces earlier age of onset of lung and probably other
cancers (29). In due time a classical TSG(s) (with homozygous inactivation in tumors)
segregating in these rare lung cancer pedigrees, could also be discovered. In any event,
the early involvement of chromosome 3p21.3 allele loss in pre-malignant lesions and
sporadic lung cancers argues that one or more of these genes play a causative role in the
origin and/or development of common, sporadic lung tumors.
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2. Cellular models in lung cancer development
Lung embryology and stem/precursor cells related to lung tumors.
From an evolutionarily perspective, lungs are a relative novelty that appeared about 400
million years ago with the purpose of supplying oxygen to the heart tissues of evolving
Vertebrates (for a review see 62). Lung development extends from branching
morphogenesis in early embryonic life, through the critical transition from fetal life to air
breathing up to the postnatal completion of alveolarization.
With about 17 million branches and 70 m2  of epithelial gas-exchange surface (63),
human lungs can support oxygen consumption ranging between 250 ml/min at rest and
5500 ml/min during hard exercise. Simultaneously the matching capillary network can
accommodate a blood flow rising from 4 l/min to 40 l/min in the transition from rest to
maximal exercise (63).
The lungs derive from the digestive tube (64). Their origin can be traced back to a ventral
outgrowth (laryngotracheal groove) that develops from the pharyngeal floor, between the
fourth and sixth pharyngeal pouches (Fig. 1) The groove deepens and grows downwards
to form a pouch-like evagination, fully open to the foregut. On either side of the groove,
two longitudinal folds of tissue (tracheo-esophogeal folds) grow together and fuse
forming a new tube (laryngeo-tracheal tube) distinct from the fore-gut. Communication
with the foregut is maintained via the longitudinally oriented laryngeal orifice.
18
Proliferation of the underlying mesenchyme forms swellings around the laryngeal orifice
from which the epiglottis, glottis, laryngeal cartilages and musculature will develop. At
the same time, the laryngeo-tracheal tube elongates downwards and penetrates the
underlying mesoderm. A distinct swelling develops at the distal end and is termed the
lung bud (respiratory diverticulum). The laryngo-tracheal endoderm constitutes the lining
of the trachea, bronchi and lung alveoli. From a histological point of view, human lung
development proceeds through five partially overlapping phases (64).
Embryonic phase (3-7 weeks).  Approximately 28 days after fertilization, the lung bud
branches from the primitive fore gut to form the left and right primary bronchial buds,
which will ultimately develop into the left and right lungs. Interaction of the epithelium
with the underlying splanchnic mesoderm controls the branching events. By the fifth
week, elongation, branching and budding of the two bronchial buds give rise to three
bronchial stems on the right and two on the left. The formation of the presumptive
bronco-pulmonary segments provides the foundation for the lobular organization of the
mature lungs and ends the embryonic phase.
Pseudo-glandular phase (7-16 weeks).  About 21 further orders of branching of the duct
system generate the presumptive conducting portion of the respiratory system, up to the
level of the terminal bronchioles. At this time, the airway lumina, narrows and lined with
pseudo-stratified squamous epithelium, are embedded within a rapidly proliferating
mesenchyme. The structure has a glandular appearance. From week 13 onward, the
lumina enlarge and the epithelium thins to a more columnar structure. The pluripotent
epithelial cells differentiate to ciliated cells and goblet cells, progressing from the
proximal to the distal regions of the developing lung.
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Canalicular phase (16-24 weeks). The terminal bronchioles divide to form two
respiratory bronchioles. This time is also characterized by extensive angiogenesis to form
a dense capillary network within the rapidly proliferating mesenchyme that surrounds the
more distal tract of the embryonic respiratory system. Dichotomous branching continues.
The cuboidal intermediate cells of the lower airways differentiate to form ciliated cells
and Clara cells. Differentiation of the mesenchyme begins during week 10 and progresses
along the developing respiratory tree giving rise to chondrocytes, stromal fibroblasts and
myoblasts. Differentiation of the mesenchyme and epithelia begins in the more proximal
regions of the airways and progresses distally. The pulmonary arteries and veins develop
in parallel with the conducting portion of the lungs.
Terminal sac phase (24-36 weeks). The primitive alveolar ducts continue branching.
The terminal sacs grow. Continued thinning of the stroma brings the capillaries into
apposition with the prospective alveoli. The cuboidal cells of the terminal sac epithelium
differentiate, via several intermediate stages, into alveolar type II cells, that secrete low
levels of surfactants. Type I pneumonocytes differentiate from cells with a type II like
phenotype. Type I cells then flatten, increasing the epithelial surface area by dilation of
the saccules, giving rise to immature alveoli. By week 26, a rudimentary though
functional blood/air barrier has formed. It is still insufficient, in case of pre-term born
infants. Maturation of the alveoli continues by further enlargement of the terminal sacs,
deposition of elastin foci and development of vascularized septa around these foci.
Alveolar phase (36 weeks - term/adult). Fully mature alveoli begin to appear around
week 36. They are characterized by thin walled inter-alveolar septa with a single layered
capillary network. The diameter of the capillaries is sufficiently large that they may span
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the alveolar walls and interact with the air spaces on both sides. New alveoli continue to
form at high rate after birth for up to 3 years. Thereafter, all components grow
proportionately until adulthood.
Histological typing of the airways epithelia. Different epithelial cell lineages are
arranged in the airways following a proximo-distal spatial pattern. The larynx is lined
with squamous epithelium and the upper airways are lined with ciliated columnar cells,
basal cells and mucous secreting cells. The apical end of the ciliated cells shows
abundant cilia (200 or more) projecting into the airways lumen. Because of their inability
to incorporate [3H]-thymidine, ciliated cells are supposed to be differentiated cells
incapable of further division, although this is still a controversial issue (65).
Basal cells are small cells that contact the basal membrane of the proximal airways, but
do not extend up to the airway lumen. Adult lung basal cells are able to incorporate [3H]-
thymidine, indicating that they normally proliferate. However, it is currently
hypothesized that these are not the stem cells of the lung epithelium (66), although they
may play a role in maintaining the lung epithelium architecture by forming desmosomes
with columnar cells and hemidesmosomes with the basal membrane. The lower airways
are lined with Clara cells. Clara cells are non-ciliated secretory cells that can be localized
throughout the respiratory tree, but in the lower airways they have been shown to be the
most actively dividing cell type during pre- and post-natal development (66). Clara cells
have been attributed a number of critical roles such as being progenitors for the ciliated
cells as well as for new Clara cells (67).
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The alveoli are lined with alveolar type I and type II epithelial cells. Type I pneumocytes
are recognized by flattened surface, protruding nucleus and complex cytoplasmic
processes. They represent 33% of the total cells but cover about 97% of the total surface.
Type I cells generate a tight sheet of cells covering the alveolar septum to form the
pulmonary capillaries by fusing to the basal lamina of vascular endothelial cells. This
structure forms the gas exchange barrier that is 0.2-0.5 mm thick. Type I do not have the
capacity to divide. Type 2 are cuboidal in shape, show abundant mitochondria,
endoplasmic reticulum, polyribosomes and a developed Golgi apparatus. They represent
67% of the total epithelial cells but cover only 3% of the surface area (68). Type II cells
secrete surfactant proteins that are responsible of reducing the surface tension in the
alveolar sacs. Type II cells are hypothesized to give rise to both type II and I upon injury
of the distal epithelium (69). Type I can also differentiate into type II cells (69). This
suggests the level of positive and negative/signaling going on to maintain a balanced
epithelial structure and function. A level of even higher complexity can be inferred from
injury studies based on the usage of different chemicals. Studies based on NO2 have
shown that Clara cells can serve as stem cells in the proximal epithelium and type II in
the alveolar epithelium. In turn, studies based on naphtalene, that selectively targets and
destroys Clara cells, showed that ciliated cells in the proximal airways and PNE in the
terminal ends – that lack ciliated cells – are responsible for repopulating the injured lung
epithelium (70). Pulmonary neuro-endocrine (PNE) cells are situated in small foci called
neuroepithelial bodies and are surrounded by the other epithelial cells in the upper
airways. PNE cells are among the first cells to differentiate from the primitive lung
epithelium. PNE cells are surrounded by a greater density of proliferating cells than
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elsewhere in the epithelium, and express a number of proliferative cytokines, including
calcitonin-like peptide and bombesin. Bombesin-like peptides (BLP) promote branching
morphogenesis and stimulate epithelial and mesenchymal cell proliferation, type II
differentiation, surfactant phospholipid synthesis, and secretion, as well as Clara cell and
PNE cell differentiation (71). It has been hypothesized that, through BLP and calcitonin-
related peptides release, PNE cells work in lung development stimulating lipofibroblast in
the lung mesenchyme to interact with the airway epithelium, thereby regulating type II
differentiation (72). PNE cells maintain a limited capacity to proliferate (73).
Lung stem cells. The many specialized cell types that make-up the lung epithelium have
lineage relationships that are not fully understood. Therefore the mechanisms by which
the pulmonary epithelial cells proliferate and terminally differentiate require much
investigation. Besides the lung epithelium continually interacts with environmental
damaging factors requiring constant tissue turnover or repair that are driven by lung-
specific stem cells. Therefore identification of adult lung stem cells would help
understand the natural history of all types of lung cancer.
Molecular evolution of initiated cells and “field cancerization” in the affected lung.
Tumors originate by clonal expansion of a single cell that has accumulated several
genetic changes that provide a growth advantage over the neighboring normal cells. It is
now accepted though that epithelial tumors rarely consists of a single clone, but rather
more often of a mixture of separate clones that also had acquired the characteristic of
genetic instability (74, 75). This genetic instability plays a central role in the Darwinian
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evolution of expanding clones of initiated cells during tumor development and growth
(76). The problem of clonality in lung cancer and the evolution of “initiated” cells to fully
malignant cells and tumors is also associated with the “field cancerization” model of
carcinogenesis in epithelial sheets (77).
Consequent to smoking damage, genetic changes occur in thousands of different sites
throughout the respiratory epithelium creating clones of initiated cells.  These clones
undergo a phase of Darwinian evolution that selects those more capable of circumventing
environmental problems such as hypoxia, malnutrition, immune system attacks, etc.
Those clones that emerge after this stage carry on the invasive step. Each patch therefore
may evolve into a distinct clonal tumor; close patches may fuse and develop further into
polyclonal tumor and so on. From a clinical perspective, finding synchronous primary
tumors is not unusual. These tumors frequently exhibit dissimilar hystology and distinct
genetic signatures (78).
Cellular evolution of the metaplasia-dysplasia-carcinoma in situ-invasive cancer
sequence of events in the affected lung.
What are the molecular events that cause the progression of an initiated cell to invasive
cancer? We must distinguish between SCLC and NSCLC. In fact, although our
knowledge of the events accompanying the rise of SCLC is quite inadequate, it seems
that these tumors may arise directly either from normal or mildly abnormal epithelia. In
NSCLC, instead, several premalignant stages have been described.
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Small cell lung cancer (SCLC).  SCLC is predominantly a central tumor. No specific
preneoplastic changes have been described for SCLC, but several smoking-related
changes such as squamous dysplasia and carcinoma in situ have been found associated
with these tumors. The bronchial epithelium accompanying SCLC was found to show
more extensive damage in terms of LOH than bronchial epithelium of patients affected
with NSCLC (89). On the basis of frequent presence of genomic abnormalities in the
morphologically normal mucosa surrounding the small cell tumor, it has been suggested
that this tumor may arise de novo from the bronchial mucosa, without going through a
stage of morphologically recognizable preinvasive lesions. Neuroendocrine cell
hyperplasia has not yet been extensively studied at the molecular level.
Non-Small cell lung cancer (NSCLC).  In contrast with what happens in SCLC,
NSCLCs appear to develop after a sequence of morphologic intermediate steps.  As
already mentioned, bronchial carcinogenesis is described as a multistep process. It
involves transformation of the normal bronchial mucosa through a continuous spectrum
of lesions consisting of basal cell hyperplasia, squamous metaplasia, dysplasia and
carcinoma in situ (CIS) (79, 80, 81). In addition to these epithelial changes, alterations of
the extracellular matrix (particularly of the epithelial basement membrane) are critical
events in the development of invasion and metastases (82). The events leading from
dysplasia/CIS to invasive disease are not completely understood but on the basis of
animal experimental models (83), hyperplasia in the stem cell compartment of the
epithelium seems to be the earliest response to environmental carcinogens. Exposure of
the lung to environmental carcinogens induces changes in the epithelium, ranging from
loss of cilia to basal cell hyperplasia (79). Genetic abnormalities accumulate before
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histopathological changes are detected. As already discussed, genetic abnormalities most
precociously found include 3p loss and 9p loss in metaplastic/hyperplastic lesions.
Dysplastic lesions are characterized by progressive loss at 3p and, later, mutations of the
p53 gene (84). Finally, 5q loss and mutations of K-RAS are found in late pre-invasive
stages. Even if the first primary is removed, the remaining lung is still harboring multiple
regions of clonal abnormalities. Continued carcinogen exposure constitutes a high risk for
developing further malignancies.
Molecular changes caused by carcinogens can persist for many years after exposure
cessation, in accordance with the long latency period often observed prior to the
development of lung cancer (85).
The term “preinvasive” does not necessarily imply that progression to invasion would
occur. In fact, some pre-invasive lesions are thought to regress after smoking cessation.
However, other bronchial epithelial hyperplasia and metaplasia may occur that are not
regarded as pre-neoplastic. These include goblet cell hyperplasia, basal cell hyperplasia,
squamous metaplasia (86). Peripheral lung cancers, predominantly adenocarcinomas,
may arise through a different mechanism and a different series of progenitor lesions (see
below). The earliest and most common chromosomal aberration in broncogenic cancers is
loss of DNA from the small arm of chromosome 3 (3p). In the mildly abnormal or even
normal epithelium surrounding the lesions 3p loss is little and focal (87). In preneoplastic
lesions the genomic loss is more pronounced (76% of hyperplasia and 86% of dysplasia
are affected by 3p losses - 88). In CIS and invasive disease, at least five loci are lost
(3p12-13, 3p14.2, 3p21, 3p21.3, 3p25). Also, losses at 9p21, 5q and 17p were described
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(89). These changes occur early and are almost invariably present in dysplasia, CIS and
invasive disease.
As expected from morphological studies, hyperproliferation seems to be an early event in
bronchial epithelium transformation. The proliferative compartment was shown to rise
from around 25% in normal epithelium to 35-40% in low and high grade dysplasias, to
85-90% in invasive squamous carcinomas (90).
p53 mutations, that follow the 3p loss, are also an early events in bronchial
carcinogenesis (91). Telomerase deregulation appears to be part of the multistage
carcinogenesis. Whereas most adult somatic cells have inactive telomerase, cancer cells
at a point reactivate their telomerase activity possibly thereby preventing telomeres
shortening and senescence. 70-80% of hyperplastic and dysplastic bronchial epithelium
showed high telomerase activity (compared to 20% in normal controls, that raised up to
95-100% in CIS - 92). K-RAS is found mutated more commonly in adenocarcinoma than
in squamous carcinoma. It appears lately in the development of some central
bronchiogenic cancers arising through the hyperplasia-dysplasia-CIS sequence (93).
Human papilloma virus (HPV) DNA has no importance in the genesis of bronchogenic
squamous carcinoma (94) although, in some studies, HPV DNA was found in 18% of
squamous carcinomas. Loss of p16 was found in moderate dysplasia and CIS, exclusively
in lesions found in cancerous lung (95). Rb loss was seen in dysplasia/CIS but molecules
in the Rb pathway (p16, Cyclin D1) were found abnormal in preinvasive squamous
bronchial lesions. In particular, Cyclin D1 overexpression was found in early lesions
(from 6% in hyperplasia to 38% of CIS lesions - 96).
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Atypical adenomatous hyperplasia (AAH).  It is now broadly believed that AAH is a
preinvasive lesion, regarded as the adenoma in an adenoma-carcinoma sequence in the
lung periphery. Immunostaining for p53 has been reported in 8-58% of lesions analyzed
(97). LOH at 3p, 9p and 17p play a role also in the evolution of this lesion as they were
found in 18%, 13% and 5% in AAH whereas the frequency raised to 67%, 50% and 17%
respectively in the corresponding carcinomatous lesions (98). K-RAS mutations were
found in 17-50% of AAH lesions (for a review see 99), suggesting that AAH represents
an early step of adenocarcinoma, although clinical data in this sense are all but
conclusive.
Molecular events in the obligatory sequence of progression to invasive cancer.
Several mutations involving tumor suppressor genes and oncogenes are required to allow
the tumorigenic transformation of a cell and the rise of an invasive cancer. In lung cancer
it has been shown that the neoplastic progression is not random but follows a pattern with
genetic and genomic changes that are tumor-specific.
An elegant experiment (100) done in Barrett oesophagus gave a detailed map of the
transformation events that happen in this type of epithelial tumor. The cytogenetic
analisis of several biopsies taken during an extended period of time, showed that LOH at
17q and 9p, are found in premalignant epithelia several years before overt cancer.
Mutations in p53 and p16 were also found before cancer, as well as hypermethylation of
p16 promoter. Using specific p53 and p16 mutations, it was possible to follow the fate of
different clones. It became evident that the process of transformation is somewhat more
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complicated than a linear succession of events. In fact, cancer appears to be made of
different clones originated from a common precursor but still evolving separately due to
the acquisition of diverse mutations. Some clones disappear in time, whereas others
become dominant in the cancer population. The general pattern of events comprises an
initial step of clonal expansion of a given starting clone. The acquisition of new
mutations projects the clonal population into a phase of genetic instability and evolution
that goes on for years and ends with the production of pre-malignant cells. Noticeably,
not all pre-malignant tissues progress to cancer.
3. Classification, diagnosis, and clinical course of lung cancers
Pathologists based on light-microscope observation of the malignant and surrounding
normal tissue morphology first classified tumors of the lung. The WHO recently revised
the histological typing of lung tumors and their pre-malignant precursor lesions,
improving the earlier WHO classifications (101) by taking into consideration some recent
advances in understanding lung tumors biology. An accurate classification of tumors is
extremely important because it affects the decision on treatment to be administered.
Clearly, a simple distinction on biopsy between SCLC and NSCLC is sufficient to predict
the clinical course of the disease and sufficient to decide the treatment strategy. However,
the morphological approach is fundamentally limited but, by necessity, still widely used
(101). In the next several years, the rapid advance of genome research (especially now in
the post-genome sequencing era) will provide with the ultimate discovery of all human
genes, including cancer genes. This will be the foundation for a genetic classification of
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cancers based on specific causative genes and cancer-gene expression profiling (102-
104). The genetic approach will perhaps gradually replace the existing intrinsically
limited morphological classification of human tumors. The new genetic typing of cancers
will recognize the well-known phenomena of genetic and clinical heterogeneity of
tumors. The genetic heterogeneity of cancers challenges our inability to distinguish
tumors that appear similar in morphology but are caused by different genes. On the other
hand, the phenomenon of clinical heterogeneity likely reflects the differences in
morphology and topical expression of different mutated alleles of the same cancer-
causing gene, may be coupled with expression of tissue-specific modifier genes and
probably with the SNP make-up of individual patients. It is widely believed that genetic
and expression profiling would better predict the clinical course of the disease and the
design and outcome of treatment modalities (104, 105).
The better understanding of cellular models in lung cancer pathogenesis (see above) and
the new histological typing of pre-malignant lesions (101), in conjunction with novel
diagnostic tools for detection of pre-invasive cancer cells have provided good options for
early detection of asymtomatic lung cancer. Combined use of novel physical methods
(such as laser-induced fluorescence endoscope bronchoscopy (106) and low-dose spiral
computed tomography (106, 107) with analyses for cytogenetic abnormalities in sputum
and bronchoalveolar lavage cells, has shifted the clinical/therapeutic paradigm towards
diagnosis and treatment of asymptomatic pre-invasive lesions to improve prognosis. In
fact, the prognosis for patients with lung cancer strongly correlates with the stage of the
disease at the time of presentation. Therefore, early identification and intervention
strategies stemming from these developments are expected to improve the usually dismal
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poor prognosis of this fatal disease.  These multi-modality approaches to early detection,
staging and therapy of specific types of lung cancers have undoubtedly improved the
clinical course and outcome of the disease at least for early diagnosed types of lung
cancers.
4. Progress in the treatment of lung cancers
Over time from the late 1950 until now, there has been slow but real progress in the
treatment of lung cancers: the overall five-year survival rate has improved from 5% in the
late 1950s to 14% in the middle 1990s (108). It continues to improve significantly due to
advances in early diagnosis and combined modality therapies against both local non-
invasive disease and more advanced forms of SCLCs and NSCLCs.  These new multi-
modality approaches include combinations of traditional treatments (surgery for
NSCLCs, radiotherapy and multi-agents chemotherapy with cytotoxics and newer drugs,
taxol and irinotecan, for SCLCs)  with new drugs developed against defined molecular
targets including signal transduction inhibitors, such as for example farnesyl transferase
(109) and tyrosine kinase inhibitors (110), and drugs that attack tumor angiogenesis (111,
112). However, a word of caution is appropriate here since to much hype was introduced
into the field. It is widely assumed and propagated in the post-genome literature that
cancer cells may have or do have specific molecular targets whose discovery will be
facilitated by the genome draft sequence. These are so called “druggable” targets for
development of new specific drugs to affect (kill) cancer cells. However, most of such
target molecules would be likely expressed in normal dividing cells of all renewable
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tissues and certainly in tissue-specific normal stem cells, which obviously the wonder
drug would also affect. The really specific molecular targets should belong to the
category of molecules that are absolutely essential for cancer cell survival and
proliferation and should not be expressed in normal dividing and stem cells. These are the
molecules we need to discover to be able to approach the goal of cancer medicine,
namely to cure cancer. Contrary to the existing beliefs we think that drugs against
oncogene targets would attack normal dividing and stem cells and at the end of the day
would be abandoned as well as oncogene antisense strategies. We have recently proposed
that the cell surface trans-membrane carbonic anhydrases induced by hypoxia and highly
expressed in tumor cells are excellent targets for drug discovery since normal dividing
cells most likely do not express these enzymes (113,114). There are also indications that
they might be altered by mutations in tumor cells. These cell proteins abundantly
expressed on the surface of hypoxic cancer cells represent also excellent targets for
immunotherapeutic strategies. Specific antibodies have been already developed and are
being tested for treatment of kidney (115) and lung (116) cancers.
Naturally, the immune system (or should we say the “immunome” in keeping with the
trend of creating “new” terminology) could be targeted against mutated proteins. It is
widely assumed that it would find cancer cells expressing these mutated proteins
operating inside the cancer cells (e.g. mutated RAS or p53 proteins) and would destroy
them. This concept in our opinion does not hold water, nevertheless cDNA based
vaccines are being produced against mutated cancer gene products that function inside
tumor cells and are vital for their survival and growth. It is probably true that you can
educate the immune system (the ‘immunome”) to recognize a mutated RAS protein as
32
non-self, but how the activated T cells would find their target inside live cancer cells
remains a mystery. The usual explanation is that, like normal cells, cancer cells
constantly process intracellular proteins to present them to the immune system, probably
to commit suicide. Normal cells occasionally present their processed proteome to the
immune system for surveillance purposes. This approach to immunotherapy of cancer
probably originated also from the well-established facts that infected cells in a “fit-of-
altruism” process the infectious agent and display it on their surface to activate the
“immunome”.  Since evolution and development of cancer cell populations is essentially
a Darwinian process, it is inconceivable that cancer cells would do a similar thing and
commit suicide. It is therefore obvious that the cell surface carbonic anhydrases would be
a much better cancer target for production of cDNA-based vaccines. Needless to say such
vaccines could also destroy normal highly differentiated cells that express these enzymes
on their surface, however these cells would be replaced by the existing not affected stem
cells. Recently, dendritic cells, potent professional antigen-presenting cells that can elicit
primary immune responses to foreign antigens, became the focus of research directed
toward their use in vaccine strategies for the treatment of cancer (117). These strategies
use tumor-pulsed dendritic cells with tumor-associated antigens including whole tumor
cell lysates (118). Undoubtedly in these experiments the tumor cell lysates contained
processed carbonic anhydrase and probably other cell surface antigens.
 The imperative of cancer research is to be able to prevent or cure cancer. The received
wisdom holds that this ultimate goal of cancer medicine is in fact achievable. It is
becoming increasingly clear that immunotherapeutic strategies as defined above and gene
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delivery therapies (gene therapy) together with common sense prevention (see below,
pp.xx) hold the keys to successful eradication of lung cancer.
Therefore, new horizons are being explored and substantial progress could be achieved in
gene therapy strategies for lung cancer. Gene therapy approaches include: (a) replacing
inactivated/lost causative TSGs with normal wild type alleles, (b) delivering genes that
become toxic under controlled conditions (suicide gene therapy,);  (c) delivering genes
that interfere with autocrine and paracrine growth factors involved in lung tumor growth
and (d) delivering genes that could augment the immune response and/or block tumor
defenses (23, 119). The major impediment of gene therapy is the absence of ideal
delivery systems (23, 119). Vectors range from viral (adenoviral and retroviral) to
chemical, liposome, formulations and finally naked recombinant cDNA expressing the
product (23, 119).  However there is constant improvement in vector construction and
formulation and there is hope that systemic delivery of therapeutic genes to primary and
disseminated lung tumors will become a reality. In this regard the discovery that the
candidate TSG HAYL2 is a receptor for the sheep lung cancer retrovirus, JSRV (47, 55),
suggests that on the base of this virus, vectors for delivering genes to bronchial epithelial
cells could be constructed.
We take the view that a combination of gene replacement strategies (delivering normal
alleles of causative TSCs) with available immunotherapeutic approaches is a preferable
course to combat lung cancer.
5. Environmental factors as causative agents in lung cancer pathogenesis and
prevention of lung cancer
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Lung cancer is a preventable malignancy since most if not all causative environmental
factors that trigger the genetic changes leading to cancer were identified and extensively
studied (120- 122). Here we focus on the modifiable risk factors such as tobacco
smoking, diet, occupational exposure, and environmental pollutants that were identified
as causative agents for lung cancer. We will also argue for early diagnosis and screening
as preventive measures that should reduce the burden of lung cancer.
About 10-20% of smokers develop lung cancer during life and smoking causes >90% of
all lung cancers (121). However since bronchioloalveolar adenocarcinomas contribute
now ~25% to lung cancer and are not associated with smoking (123) only ~75% of lung
cancers should be attributed to smoking. Tobacco consumption is also causally related to
cancers of the colon, mouth, larynx, esophagus, bladder, kidney and pancreas increasing
the burden of cancer death due to smoking to more than 30% in the United States.
Common sense dictates that tobacco use should be avoided especially in young age since
early onset of smoking is related to higher risk of lung and colon cancers. Therefore a
broad range of social measures are now mobilized to succeed in preventing adolescent
smoking and persuade long term adult smokers to stop smoking. Cessation of smoking
usually reduced the risk of lung cancer after 5 years from cessation; the risk continues to
decline further with duration of time (120-122). Benzo[a]pyrene the most active of the 20
carcinogen in tobacco smoke and tar was shown to rapidly (within minutes) attack and
destroy promoters of actively transcribed genes followed by incomplete repair of some
(124); this mechanism could lead to silencing cancer-causing TSGs and therefore initiate
the malignant transformation in lung and other susceptible tissues. Footprint mutations
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due to benzo[a]pyrene in other genes (such as p53) were shown (125). Individual
variability in lung cancer risk and carcinogen metabolism, mainly via metabolic
polymorphisms in the carcinogen metabolizing enzymes (126, 127) may explain
differential susceptibility of smokers to lung cancer. In addition, some of the known
occupational lung carcinogens, including asbestos, arsenic, coal gas, chromates, nickel,
and silica (120) were shown to interact with smoking to increase the risk of lung cancer
multiplicatively (i.e. effects proportional to the effect of smoking). However, it was
shown in cohort studies that the relative risk of lung cancer from asbestos exposure is
about twice as high in non-smokers compared to smokers and recently concluded that the
multiplicative hypothesis is untenable (120, 128). This suggests that the effects of
combinations of smoking with other environmental factors and carcinogens remain to be
carefully studied. As of asbestos exposure the recently conducted meta-analysis study
concluded “that besides mesothelioma, lung cancer is the only malignancy that
demonstrates unequivocal association with asbestos exposure” (128, 129).
Recently an international group of scientists proposed an immediate ban on production
and use of asbestos products (130). Other risk factors such as arsenic and industrial
pollutants, radon and radiation exposure from occupational, medical and environmental
sources, and diet and nutrition, collectively cause about 10-15% of lung cancers (121,
122) not directly related to smoking.
Clearly, we know now that most if not all lung cancers are caused by environmental
factors that interact with the lung epithelial cells directly or after being modified by
carcinogen-bioactivating (detoxifying) enzymes to introduce mutations into cancer-
causing gene loci, TSGs and oncogenes. We also know that the current epidemic of lung
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cancers continues unabated despite all efforts to limit contact with environmental risk
factors. The legacy of decades of tobacco use in a sizable proportion of the current US
population suggests we need to turn to strategies of early diagnosis and chemoprevention
to reduce deaths and suffering of those destined to develop lung cancer. The potential of
new screening procedures to detect even pre-malignant lesions in lung epithelium in
high-risk populations have been recently demonstrated by the results from the Early Lung
Cancer Action Project (131); these observations emphasize that lives could be saved by
early detection and treatment of asymptomatic lung cancer patients (132). These findings
also provide the rationale for development of chemoprevention strategies for patients
with asymptomatic and localized disease (133). In principle, chemopreventive substances
aim to prevent genetic damage inflicted by carcinogenic agents or aid in DNA and/or
tissue repair to prevent mutations or eliminate initiated cells. Retinoids taken orally have
shown recently promising results in preventing oral cancer (134) and reducing risk of
second primary cancers in patients with head and neck cancer (134). However
chemoprevention of lung cancer (135, 136) in large-scale clinical trials such as
EUROSCAN (i.e. the European Study on Chemoprevention With Vitamin A and N-
Acetylserine) met with little or no success at all (135-137). Similar negative results were
obtain in other large-scale studies, namely, the ATBC (Alpha-Tocopherol, Beta
Carotene) in Finland (136) and the CARET (Beta-Carotene and Retinol Efficacy Trial) in
the United States (138) suggesting that prior carefully designed basic mechanistic studies
are needed to attempt to approach chemoprevention of lung cancer. However a word of
optimism is also needed in this difficult and already frustrating area of cancer research;
an increasing number of agents should keep clinicians hopeful.
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6. Hope and pessimism still rule in cancer medicine
Since the 1970s when President R. Nixon inaugurated the War on Cancer Act the United
States spent enormous amount of monies and effort to discover the genetic causes of
cancer and find a cure. At that time (the 1970s when one of us, MIL, was still young)
there was a cartoon shown on the International Congress of Biochemistry depicting the
cancer problem from different perspectives. It showed a researcher in a blue lab-coat
saying he just made a discovery that would lead to a new powerful treatment, next to him
was a skeptical physicians sitting on the patients bed and saying that “they” always come-
up with things that wouldn’t work. The desperate patient was asking for anything that
would help him. Did this picture change?
Currently we know much about cancer causation but the magic bullet/cure is still elusive.
However we take the view that for several reasons now is really the time for some
optimism. Firstly, the soon to be completed (2005?) and understood (2020?) human
genome sequence holds the promise that all cancer genes will be identified and their
functions deciphered. Secondly, genetic individual differences that determine
susceptibility to environmental risk factors and control the response to treatment
modalities also would be identified along with ways to manipulate them. Thirdly, with
the genes and their products in hand new modalities would be found to prevent and
combat/cure cancer. This optimistic view has become the core belief of both researchers
and clinicians facing the constant onslaught of cancer.
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